✦ LIBER ✦

INCIDENCE AND MEANING OF THE " e " DETERMINANT AMONG HEPATITIS-B-ANTIGEN POSITIVE PATIENTS WITH ACUTE AND CHRONIC LIVER DISEASES

✍ Scribed by Nielsen, J.O; Dietrichson, O; Juhl, E

Book ID: 122096820
Publisher: The Lancet
Year: 1974
Tongue: English
Weight: 401 KB
Volume: 304
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(74)91127-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of hepatitis B surface antige

Comparison of hepatitis B surface antigen and e antigen in predicting liver histology in hepatitis B e antigen-positive chronic hepatitis B patients

✍ Wang, Hong; Yan, Rong; Zhou, Yin; Wang, Ming Shan; Ruo, Guo Qin; Cheng, Mei Juan 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 502 KB

Antiviral activity and safety of LB80380

Antiviral activity and safety of LB80380 in hepatitis B e antigen–positive chronic hepatitis B patients with lamivudine-resistant disease

✍ Man-Fung Yuen; Kwang-Hyub Han; Soon-Ho Um; Seung Kew Yoon; Hye-Ryon Kim; John Ki 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 380 KB 👁 1 views

We aimed to determine the antiviral activity and safety of a new nucleotide analogue, LB80380, in chronic hepatitis B (CHB) patients with lamivudine-resistant virus. Sixty-five patients with lamivudine-resistant virus were randomized to receive five ascending daily doses (30, 60, 90, 150, 240 mg) of

Characterization of viral kinetics in pa

Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B

✍ I-Chin Wu; Nan-Haw Chow; Pin-Nan Cheng; Wen-Chun Liu; Kung-Chia Young; Wei-Lun C 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract A study was conducted during a 1 year follow‐up to characterize the viral kinetics in hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B and to develop a model of predicting the probability of spontaneous HBeAg seroconversion. Fifty‐seven patients with HBeAg‐positive chronic hep

A 1-Year Trial of Telbivudine, Lamivudin

A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B

✍ Ching-Lung Lai; Nancy Leung; Eng-Kiong Teo; Myron Tong; Florence Wong; Hie-Won H 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 203 KB

Analysis of the precore DNA sequence and

Analysis of the precore DNA sequence and detection of precore antigen in liver specimens from patients with anti-hepatitis b e—positive chronic hepatitis

✍ Hans Peter Dienes; Guido Gerken; Bernd Goergen; Klaus Heermann; Dr. Wolfram Gerl 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 896 KB

A number of naturally occurring hepatitis B virus (HBV) mutants unable to synthesize the hepatitis B e antigen (HBeAg) have been identified in patients characterized by HBV DNA and anti-HBe in their serum. Because the analysis of the HBV-associated DNA and antigens in the liver tissue is still not c

Efficacy of lamivudine in patients with

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60